S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0 – September 2015, AWMF-Registernummer: 021/023OL)

Schlüsselwörter

Ösophaguskarzinom

Key words

esophageal cancer

• Literatur

• 1 RKI and GEKID. Krebs in Deutschland 2009/2010, in Beiträge zur Gesundheitsberichterstattung des Bundes. Berlin: Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V; 2013
• 2 Kreienberg R et al. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. AWMF-Register-Nummer: 032 – 045OL 2012
• 3 Beauchamp TL, Childress JF. Priciples of Biomedical Ethics. Oxford University Press. 5 th ed. 2001
• 4 (Muster)-Berufsordnung für die in Deutschland tätigen Ärztinnen und Ärzte (Stand 2011). www.bundesaerztekammer.de (Letzter Aufruf am 10.03.2015)
• 5 Bundesministerium der Justiz und des Verbraucherschutzes (2013). Gesetz zur Verbesserung der Rechte von Patientinnen und Patienten. Drucksache 7/13. www.bmjv.de/DE/Buerger/gesellschaft/Patientenrechte/node.html
• 6 Tramacere I, La Vecchia C, Negri E. Tobacco smoking and esophageal and gastric cardia adenocarcinoma: a meta-analysis. Epidemiology 2011; 22: 344-349
• 7 Lee CH et al. Anatomical subsite discrepancy in relation to the impact of the consumption of alcohol, tobacco and betel quid on esophageal cancer. Int J Cancer 2007; 120: 1755-1762
• 8 Pandeya N et al. Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants?. Gut 2010; 59: 31-38
• 9 Islami F et al. Alcohol drinking and esophageal squamous cell carcinoma with focus on light-drinkers and never-smokers: a systematic review and meta-analysis. Int J Cancer 2011; 129: 2473-2484
• 10 Bagnardi V et al. Light alcohol drinking and cancer: a meta-analysis. Ann Oncol 2012;
• 11 Freedman ND et al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut 2011; 60: 1029-1037
• 12 Pandeya N et al. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. Gastroenterology 2009; 136: 1215-1224, e1–2
• 13 Tramacere I et al. A meta-analysis on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk. Ann Oncol 2012; 23: 287-297
• 14 Moehler M et al. S3-Leitlinie „Magenkarzinom”. Z Gastroenterol 2011; 49: 461-531
• 15 Guh DP et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88
• 16 Ryan AM et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol 2011; 35: 309-319
• 17 Turati F et al. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol 2013; 24: 609-617
• 18 O'Doherty MG et al. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. Gut 2012; 61: 1261-1268
• 19 Leeuwenburgh I et al. Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol 2010; 105: 2144-2149
• 20 Zendehdel K et al. Risk of esophageal adenocarcinoma in achalasia patients, a retrospective cohort study in Sweden. Am J Gastroenterol 2011; 106: 57-61
• 21 Ji J, Hemminki K. Familial risk for esophageal cancer: an updated epidemiologic study from Sweden. Clin Gastroenterol Hepatol 2006; 4: 840-845
• 22 Morton LM et al. Risk of treatment-related esophageal cancer among breast cancer survivors. Ann Oncol 2012; 23: 3081-3091
• 23 Zablotska LB et al. Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am J Epidemiol 2005; 161: 330-337
• 24 Levi F et al. Increased risk of esophageal cancer after breast cancer. Ann Oncol 2005; 16: 1829-1831
• 25 Roychoudhuri R et al. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 2004; 91: 868-872
• 26 Okonta KE, Tettey M, Abubakar U. In patients with corrosive oesophageal stricture for surgery, is oesophagectomy rather than bypass necessary to reduce the risk of oesophageal malignancy?. Interact Cardiovasc Thorac Surg 2012; 15: 713-715
• 27 Lagergren J et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831
• 28 Velanovich V et al. Relationship of gastroesophageal reflux disease with adenocarcinoma of the distal esophagus and cardia. Dig Surg 2002; 19: 349-353
• 29 Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 2003; 98: 940-948
• 30 Chak A et al. Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer 2006; 107: 2160-2166
• 31 Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2010; 32: 1222-1227
• 32 Hvid-Jensen F et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365: 1375-1383
• 33 Wani S et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 220-227 ; quiz e26
• 34 Anaparthy R et al. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol 2013; 11: 1430-1436
• 35 Gaddam S et al. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology 2013; 145: 548-553.e1
• 36 Desai TK et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012; 61: 970-976
• 37 Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett's esophagus compared with the general population: a population-based cohort study. Gastroenterology 2013; 144: 1375-1383, 1383.e1
• 38 Koop H et al. S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013. Z Gastroenterol 2014; 52: 1299-1346
• 39 Steinberg J et al. Koinzidenz von Plattenepithelkarzinomen der Speiseröhre und Kopf-Hals-Karzinomen: Risiko und Früherkennung. Tumor Diagn u Ther 2008; 29: 35-39
• 40 Moschler O et al. Chromoendoscopy is a valuable tool for screening of high-risk patients with head and neck cancer for early detection of esophageal cancer. Digestion 2006; 73: 160-166
• 41 Ljung R, Martin L, Lagergren J. Oral disease and risk of oesophageal and gastric cancer in a nationwide nested case-control study in Sweden. Eur J Cancer 2011; 47: 2128-2132
• 42 Allum WH et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2011; 60: 1449-1472
• 43 Rothwell PM et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41
• 44 Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-527
• 45 Cuzick J et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2015; 26: 47-57
• 46 Cook NR et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159: 77-85
• 47 Cardwell CR et al. Exposure to oral bisphosphonates and risk of cancer. Int J Cancer 2012; 131: E717-E725
• 48 Green J et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010; 341: c4444
• 49 Oh YH, Yoon C, Park SM. Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies. World J Gastroenterol 2012; 18: 5779-5788
• 50 Haber SL, McNatty D. An evaluation of the use of oral bisphosphonates and risk of esophageal cancer. Ann Pharmacother 2012; 46: 419-423
• 51 Andrici J, Tio M, Eslick GD. Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer. Aliment Pharmacol Ther 2012; 36: 708-716
• 52 Bjelakovic G et al. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev 2008; CD004183
• 53 Vigen C, Bernstein L, Wu AH. Occupational physical activity and risk of adenocarcinomas of the esophagus and stomach. Int J Cancer 2006; 118: 1004-1009
• 54 Stehle P. Deutsche Gesellschaft für Ernährung. 12. Ernährungsbericht 2012. European Journal of Nutrition an Food Safety 2012; 4: 2347-2564
• 55 Liu J et al. Intake of fruit and vegetables and risk of esophageal squamous cell carcinoma: a meta-analysis of observational studies. Int J Cancer 2013; 133: 473-485
• 56 Choi Y et al. Consumption of red and processed meat and esophageal cancer risk: meta-analysis. World J Gastroenterol 2013; 19: 1020-1029
• 57 Keszei AP et al. Red and processed meat consumption and the risk of esophageal and gastric cancer subtypes in The Netherlands Cohort Study. Ann Oncol 2012; 23: 2319-2326
• 58 Huang W et al. Red and processed meat intake and risk of esophageal adenocarcinoma: a meta-analysis of observational studies. Cancer Causes Control 2013; 24: 193-201
• 59 Jakszyn P et al. Meat and heme iron intake and esophageal adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition study. Int J Cancer 2013; 133: 2744-2750
• 60 Salehi M et al. Meat, fish, and esophageal cancer risk: a systematic review and dose-response meta-analysis. Nutr Rev 2013; 71: 257-267
• 61 Palmer JB, Drennan JC, Baba M. Evaluation and treatment of swallowing impairments. Am Fam Physician 2000; 61: 2453-2462
• 62 Behrens A et al. How safe is sedation in gastrointestinal endoscopy? A multicentre analysis of 388404 endoscopies and analysis of data from prospective registries of complications managed by members of the Working Group of Leading Hospital Gastroenterologists (ALGK). Z Gastroenterol 2013; 51: 432-436
• 63 Hori K et al. Lugol-voiding lesions are an important risk factor for a second primary squamous cell carcinoma in patients with esosphageal cancer or head and neck cancer. Am J Gastroenterol 2011; 106: 858-866
• 64 Qumseya BJ et al. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett's esophagus: a meta-analysis and systematic review. Clin Gastroenterol Hepatol 2013; 11: 1562-1570.e1–2
• 65 Curvers WL et al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology 2010; 139: 1106-1114
• 66 Uedo N et al. Role of narrow band imaging for diagnosis of early-stage esophagogastric cancer: current consensus of experienced endoscopists in Asia-Pacific region. Dig Endosc 2011; 23: 58-71
• 67 Curvers WL et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010; 105: 1523-1530
• 68 Lim H et al. Clinical significance of early detection of esophageal cancer in patients with head and neck cancer. Gut Liver 2015; 9: 159-165
• 69 Katada C et al. Risk of superficial squamous cell carcinoma developing in the head and neck region in patients with esophageal squamous cell carcinoma. Laryngoscope 2012; 122: 1291-1296
• 70 Chow TL et al. Prediction of simultaneous esophageal lesions in head and neck squamous cell carcinoma: a multivariate analysis. Arch Otolaryngol Head Neck Surg 2009; 135: 882-885
• 71 Muto M et al. Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc 2002; 56: 517-521
• 72 Thosani N et al. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc 2012; 75: 242-253
• 73 Puli SR et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol 2008; 14: 1479-1490
• 74 van Vliet EP et al. Staging investigations for oesophageal cancer: a meta-analysis. BrJ Cancer 2008; 98: 547-557
• 75 Tranchemontagne J. Stadification initiale du cancer de l'oesophage: revue systematique sur la performance des methodes diagnostiques. Initial staging of oesophageal cancer: systematic review of the performance of diagnostic methods. Agence d'evaluation des technologies et des modes d'intervention en sante (AETMIS). ETMIS 5. Montreal: 2009
• 76 Takizawa K et al. Lymph node staging in esophageal squamous cell carcinoma: a comparative study of endoscopic ultrasonography versus computed tomography. J Gastroenterol Hepatol 2009; 24: 1687-1691
• 77 Stiles BM et al. Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease. Ann Thorac Surg 2011; 92: 491-496 ; discussion 496–4988
• 78 Oldenburg A, Albrecht T. Sonografische Leberdiagnostik bei Tumorpatienten ohne und mit Kontrastmittel. Ultraschall in Med 2008; 29: 488-498
• 79 Kinkel K et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002; 224: 748-756
• 80 Piscaglia F et al. Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. BMC Cancer 2007; 7: 171
• 81 Dietrich CF et al. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 2006; 12: 1699-1705
• 82 Albrecht T et al. Improved detection of hepatic metastases with pulse-inversion US during the liver-specific phase of SHU 508A: multicenter study. Radiology 2003; 227: 361-370
• 83 Hanle MM et al. Screening for liver metastases in women with mammary carcinoma: comparison of contrast-enhanced ultrasound and magnetic resonance imaging. Clin Imaging 2011; 35: 366-370
• 84 Seitz K et al. Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions – prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreilandertreffen 2008, Davos. Ultraschall in Med 2009; 30: 383-389
• 85 Seitz K et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI – a prospective comparison in 269 patients. Ultraschall in Med 2010; 31: 492-499
• 86 Strobel D et al. Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioma and focal nodular hyperplasia in the differential diagnosis of 1349 liver lesions in contrast-enhanced ultrasound (CEUS). Ultraschall in Med 2009; 30: 376-382
• 87 Westwood M et al. Contrast-enhanced ultrasound using SonoVue(R) (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess 2013; 17: 1-243
• 88 Doldi SB et al. Ultrasonographic evaluation of the cervical lymph nodes in preoperative staging of esophageal neoplasms. Abdom Imaging 1998; 23: 275-277
• 89 Lerut T, Stordeur S, Verleye L et al. Update of the national guideline on upper gastrointestinal cancer – Appendix. Good Clinical Practice (GCP). Brussels: Belgian Health Care Knowledge Centre (KCE); 2012 KCE Report 179 S. D/2012/10.273/35
• 90 Schreurs LM et al. Current relevance of cervical ultrasonography in staging cancer of the esophagus and gastroesophageal junction. Eur J Radiol 2008; 67: 105-111
• 91 Van Overhagen H et al. Improved assessment of supraclavicular and abdominal metastases in oesophageal and gastro-oesophageal junction carcinoma with the combination of ultrasound and computed tomography. Br J Radiol 1993; 66: 203-208
• 92 van Vliet EP et al. Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis. Br J Cancer 2007; 97: 868-876
• 93 Omloo JM et al. Additional value of external ultrasonography of the neck after CT and PET scanning in the preoperative assessment of patients with esophageal cancer. Dig Surg 2009; 26: 43-49
• 94 van Overhagen H et al. Assessment of distant metastases with ultrasound-guided fine-needle aspiration biopsy and cytologic study in carcinoma of the esophagus and gastroesophageal junction. Gastrointest Radiol 1992; 17: 305-310
• 95 van Overhagen H et al. Supraclavicular lymph node metastases in carcinoma of the esophagus and gastroesophageal junction: assessment with CT, US, and US-guided fine-needle aspiration biopsy. Radiology 1991; 179: 155-158
• 96 Mori S et al. Preoperative assessment of resectability for carcinoma of the thoracic esophagus. Part I. Esophagogram and azygogram. Ann Surg 1979; 190: 100-105
• 97 Kumbasar B. Carcinoma of esophagus: radiologic diagnosis and staging. Eur J Radiol 2002; 42: 170-180
• 98 Fiore D et al. Multimodal imaging of esophagus and cardia cancer before and after treatment. Radiol Med 2006; 111: 804-817
• 99 Moreto M. Diagnosis of esophagogastric tumors. Endoscopy 2005; 37: 26-32
• 100 Kim TJ et al. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics 2009; 29: 403-421
• 101 Pech O et al. The Impact of Endoscopic Ultrasound and Computed Tomography on the TNM Staging of Early Cancer in Barrett's Esophagus. Am J Gastroenterol 2006; 101: 2223-2229
• 102 Quint LE. Thoracic complications and emergencies in oncologic patients. Cancer Imaging 2009; 9 Spec No A: S75–82.
• 103 Makarawo TP et al. Water as a contrast medium: a re-evaluation using the multidetector-row computed tomography. Am Surg 2013; 79: 728-733
• 104 Kamel IR, Fishman EK. Recent advances in CT imaging of liver metastases. Cancer J 2004; 10: 104-120
• 105 Network, S.I.G., Scottish Intercollegiate Guidelines Network Management of oesophageal and gastric cancer. A national clinical guideline. 2006
• 106 Gollub MJ et al. Pelvic CT in patients with esophageal cancer. Am J Roentgenol 2005; 184: 487-490
• 107 Ba-Ssalamah A et al. Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological results. Eur Radiol 2011; 21: 2326-2335
• 108 Takizawa K et al. Lymph node staging in esophageal squamous cell carcinoma: a comparative study of endoscopic ultrasonography versus computed tomography. J Gastroenterol Hepatol 2009; 24: 1687-1691
• 109 Choi J et al. Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc 2010; 24: 1380-1386
• 110 Lowe VJ et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 2005; 7: 422-430
• 111 Heger U et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?. Ann Surg Oncol 2014; 21: 1739-1748
• 112 Blank S et al. A reliable risk score for stage IV esophagogastric cancer. Eur J Surg Oncol 2013; 39: 823-830
• 113 Blank S et al. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. Langenbecks Arch Surg 2013; 398: 211-220
• 114 Blank S et al. Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. Langenbecks Arch Surg 2012; 397: 45-55
• 115 Sohn KM et al. Comparing MR imaging and CT in the staging of gastric carcinoma. Am J Roentgenol 2000; 174: 1551-1557
• 116 Anzidei M et al. Diagnostic performance of 64-MDCT and 1.5-T MRI with high-resolution sequences in the T staging of gastric cancer: a comparative analysis with histopathology. Radiol Med 2009; 114: 1065-1079
• 117 Lauenstein TC et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology 2004; 233: 139-148
• 118 Wong R, Malthaner R. Esophageal cancer: a systematic review. Curr Probl Cancer 2000; 24: 297-373
• 119 Weber MA et al. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction. J Gastrointestin Liver Dis 2013; 22: 45-52
• 120 Quint LE, Bogot NR. Staging esophageal cancer. Cancer Imaging 2008; 8 Spec No A: S33–S42
• 121 Medical Services Advisory Committee. Positron emission tomography for oesophageal and gastric cancer: assessment report / prepared by the Medical Services Advisory Committee with the assistance of Silke Walleser et al. Australia: 2008
• 122 1591-223X, D.-I., Servizio Santario Regionale ER. Dossier 209-2011 ISSN 1591–223X. 2011
• 123 Choi JY et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 2000; 41: 808-815
• 124 Flamen P et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18: 3202-3210
• 125 Downey RJ et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003; 21: 428-432
• 126 Heeren PA et al. Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med 2004; 45: 980-987
• 127 Noble F et al. Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study. Clin Radiol 2009; 64: 699-705
• 128 Kato H, Nakajima M. The efficacy of FDG-PET for the management of esophageal cancer: review article. Ann Thorac Cardiovasc Surg 2012; 18: 412-419
• 129 Hsu WH et al. Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma. Ann Thorac Surg 2009; 87: 1564-1568
• 130 Barber TW et al. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med 2012; 53: 864-871
• 131 Cervino AR et al. Positron emission tomography/computed tomography and esophageal cancer in the clinical practice: How does it affect the prognosis?. J Cancer Res Ther 2012; 8: 619-625
• 132 Varghese Jr TK et al. The society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Ann Thorac Surg 2013; 96: 346-356
• 133 IQWIG. Abschlussbericht Nr.172 zur "Positronen-Emissionstomografie (PET) und (PET/CT) bei Ösophaguskarzinom. 2013
• 134 CMS final decision on PET in solid tumors. J Nucl Med 2013; 54: 11n
• 135 Osugi H et al. Bronchoscopic ultrasonography for staging supracarinal esophageal squamous cell carcinoma: impact on outcome. World J Surg 2003; 27: 590-594
• 136 Wakamatsu T et al. Usefulness of preoperative endobronchial ultrasound for airway invasion around the trachea: esophageal cancer and thyroid cancer. Respiration 2006; 73: 651-657
• 137 Omloo JM et al. Value of bronchoscopy after EUS in the preoperative assessment of patients with esophageal cancer at or above the carina. J Gastrointest Surg 2008; 12: 1874-1879
• 138 Riedel M et al. Preoperative bronchoscopic assessment of airway invasion by esophageal cancer: a prospective study. Chest 1998; 113: 687-695
• 139 Baisi A, Bonavina L, Peracchia A. Bronchoscopic staging of squamous cell carcinoma of the upper thoracic esophagus. Arch Surg 1999; 134: 140-143
• 140 Imadahl A et al. Is bronchoscopy a useful additional preoperative examination in esophageal carcinoma?. Langenbecks Arch Chir 1990; 375: 326-329
• 141 Nieveen van Dijkum EJ et al. The efficacy of laparoscopic staging in patients with upper gastrointestinal tumors. Cancer 1997; 79: 1315-1319
• 142 de Graaf GW et al. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol 2007; 33: 988-992
• 143 Nath J et al. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. Br J Surg 2008; 95: 721-726
• 144 Krasna MJ et al. Thoracoscopic staging of esophageal cancer: a prospective, multiinstitutional trial. Cancer and Leukemia Group B Thoracic Surgeons. Ann Thorac Surg 1995; 60: 1337-1340
• 145 Krasna MJ et al. CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer. Ann Thorac Surg 2001; 71: 1073-1079
• 146 Luketich JD et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999; 68: 1133-1136 ; discussion 1136–7
• 147 Wang GQ et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut 2005; 54: 187-192
• 148 Kuwano H. Peculiar histopathologic features of esophageal cancer. Surg Today 1998; 28: 573-575
• 149 Bosman F et al. WHO Classification of Tumors of the Digestive System. 4 th edition. Lyon: IARC; 2010
• 150 Schnell TG et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120: 1607-1619
• 151 Reid BJ et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988; 19: 166-178
• 152 Skacel M et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000; 95: 3383-3387
• 153 Montgomery E et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001; 32: 368-378
• 154 Ormsby AH et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002; 51: 671-676
• 155 Kerkhof M et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007; 50: 920-927
• 156 Wani S et al. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett's dysplasia. Clin Gastroenterol Hepatol 2010; 8: 783-788
• 157 Bennett C et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 143: 336-346
• 158 Brown IS, Whiteman DC, Lauwers GY. Foveolar type dysplasia in Barrett esophagus. Mod Pathol 2010; 23: 834-843
• 159 Odze RD. What the gastroenterologist needs to know about the histology of Barrett's esophagus. Curr Opin Gastroenterol 2011; 27: 389-396
• 160 Rucker-Schmidt RL et al. Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am J Surg Pathol 2009; 33: 886-893
• 161 Mahajan D et al. Grading of gastric foveolar-type dysplasia in Barrett's esophagus. Mod Pathol 2010; 23: 1-11
• 162 Demicco EG et al. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol 2011; 24: 1177-1190
• 163 Chandrasoma P et al. A proposal for a new validated histological definition of the gastroesophageal junction. Hum Pathol 2006; 37: 40-47
• 164 Sharma P et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006; 4: 566-572
• 165 Gatenby PA et al. Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus. Dis Esophagus 2009; 22: 133-142
• 166 Weston AP et al. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001; 96: 1355-1362
• 167 Reid BJ et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000; 95: 1669-1676
• 168 Buttar NS et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122: 1101-1112
• 169 Montgomery E et al. Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up. Am J Gastroenterol 2002; 97: 27-31
• 170 Harrison R et al. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 2007; 102: 1154-1161
• 171 Wittekind C. 2010 TNM system: on the 7th edition of TNM classification of malignant tumors. Pathologe 2010; 31: 331-332
• 172 Fritz A et al. International Classification of Diseases for oncology (ICD-O). 3rd ed. Geneva: WHO; 2000
• 173 Wittekind C, Asamura H, Sobin LH. TNM Atlas. Illustrated guide to the TNM Classification of Malignant Tumours. 6th edition. Oxford: Wiley Blackwell; 2014
• 174 Wittekind C. TNM-Supplement. Erläuterungen zur einheitlichen Anwendung. 4. Auflage. Wiley-Blackwell; [Übersetzung der Englischen Ausgabe: Wittekind Ch, Compton CC, Brierley J, Sobin LH (eds.) TNM Supplement. Commentaries on uniform use. 4th ed.] 2013
• 175 Kodama M, Kakegawa T. Treatment of superficial cancer of the esophagus: a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan. Surgery 1998; 123: 432-439
• 176 Bollschweiler E et al. Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors?. J Surg Oncol 2006; 94: 355-363
• 177 Rice TW et al. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg 1998; 65: 787-792
• 178 ©, T.A.H.M.D.C. The American Heritage® Medical Dictionary Copyright ©. Houghton Mifflin Company; 2007
• 179 Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85: 1457-1459
• 180 Kato H et al. Evaluation of the new (1987) TNM classification for thoracic esophageal tumors. Int J Cancer 1993; 53: 220-223
• 181 Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241-2252
• 182 Gospodarowicz MK, O’Sullivan B, Sobin LH. International Union Against Cancer (UICC). Prognostic Factors in Cancer. 3rd ed. New York: Wiley; 2006
• 183 Roder JD et al. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 1994; 81: 410-413
• 184 Hermanek P. Tumors of the gastrointestinal tract and the pancreas: histopathology, staging and prognosis. Anticancer Res 1999; 19: 2393-2396
• 185 Dexter SP et al. Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut 2001; 48: 667-670
• 186 Khan OA et al. Prognostic significance of circumferential resection margin involvement following oesophagectomy for cancer. Br J Cancer 2003; 88: 1549-1552
• 187 Brucher BL et al. Achalasia and esophageal cancer: incidence, prevalence, and prognosis. World J Surg 2001; 25: 745-749
• 188 Sarbia M et al. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994; 74: 2218-2223
• 189 Mandard AM et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686
• 190 Becker K et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98: 1521-1530
• 191 Langer R et al. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol 2009; 22: 1555-1563
• 192 Becker K et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 2011; 253: 934-939
• 193 Langer R et al. A multifactorial histopathologic score for the prediction of prognosis of resected esophageal adenocarcinomas after neoadjuvant chemotherapy. Ann Surg Oncol 2014; 21: 915-921
• 194 Wu TT et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol 2007; 31: 58-64
• 195 Mirza A et al. Assessment of Histopathological Response in Gastric and Gastro-Oesophageal Junction Adenocarcinoma following Neoadjuvant Chemotherapy: Which Scoring System to Use?. ISRN Pathology 2012; 2012: 8
• 196 Karamitopoulou E et al. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches. Am J Surg Pathol 2014; 38: 1551-1556
• 197 Ancona E et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91: 2165-2174
• 198 Rohatgi P et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005; 104: 2365-2372
• 199 Schneider PM et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005; 242: 684-692
• 200 Meredith KL et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol 2010; 17: 1159-1167
• 201 Chirieac LR et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103: 1347-1355
• 202 Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
• 203 Bang Y. Pathological features of advanced gastric cancer (GC): Relatationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009; 27: 15s
• 204 Satoh T et al. Quality of life in the trastuzumab for gastric cancer trial. Oncologist 2014; 19: 712-719
• 205 Weimann A et al. Significance of preoperative weight loss for perioperative metabolic adaptation and surgical risk in patients with tumors of the upper gastrointestinal tract. Langenbecks Arch Chir 1992; 377: 45-52
• 206 Saito T et al. Factors related to malnutrition in patients with esophageal cancer. Nutrition 1991; 7: 117-121
• 207 Falkner D, Plato R, Weimann A. Die Wertigkeit der Feinnadelkatheterjejunostomie in der postoperativen enteralen Ernährung nach Ösophagusresektion. Deutsche Gesellschaft für Chirurgie. 131. Kongress der Dt. Gesellschaft für Chirurgie. Berlin: 25.-28.03.2014
• 208 van Stijn MF et al. Preoperative nutrition status and postoperative outcome in elderly general surgery patients: a systematic review. JPEN J Parenter Enteral Nutr 2013; 37: 37-43
• 209 Weimann A et al. Clinical nutrition in surgery. Guidelines of the German Society for Nutritional Medicine. Chirurg 2014; 85: 320-326
• 210 Arends J et al. S3-Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin. Klinische Ernährung in der nicht-chirurgischen Onkologie. Aktuel Ernährungsmed in press 2015;
• 211 Pech O et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg 2011; 254: 67-72
• 212 Prasad GA et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 2009; 137: 815-823
• 213 Ell C et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118: 670-677
• 214 Ell C et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007; 65: 3-10
• 215 Pech O et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57: 1200-1206
• 216 Pech O et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014; 146: 652-660.e1
• 217 Chennat J et al. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience. Am J Gastroenterol 2009; 104: 2684-2692
• 218 Moss A et al. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol 2010; 105: 1276-1283
• 219 Pouw RE et al. Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients. Gut 2010; 59: 1169-1177
• 220 Pouw RE et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010; 8: 23-29
• 221 van Vilsteren FG et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011; 60: 765-773
• 222 Manner H et al. Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol 2008; 103: 2589-2597
• 223 Manner H et al. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol 2013; 11: 630-635 ; quiz e45
• 224 Alvarez Herrero L et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy 2010; 42: 1030-1036
• 225 Fitzgerald RC et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014; 63: 7-42
• 226 Guo HM et al. Endoscopic submucosal dissection vs endoscopic mucosal resection for superficial esophageal cancer. World J Gastroenterol 2014; 20: 5540-5547
• 227 Neuhaus H et al. Endoscopic submucosal dissection plus radiofrequency ablation of neoplastic Barrett's esophagus. Endoscopy 2012; 44: 1105-1113
• 228 Kagemoto K et al. Clinical outcomes of endoscopic submucosal dissection for superficial Barrett's adenocarcinoma. Gastrointest Endosc 2014; 80: 239-245
• 229 Probst A et al. Endoskopische Submukosadissektion (ESD) im Ösophagus. Z Gastroenterol 2013; 51: K233
• 230 Feith M, Stein HJ, Siewert JR. Pattern of lymphatic spread of Barrett's cancer. World J Surg 2003; 27: 1052-1057
• 231 Holscher AH et al. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg 2011; 254: 802-807 ; discussion 807 – 808
• 232 Zemler B et al. Early Barrett's carcinoma: the depth of infiltration of the tumour correlates with the degree of differentiation, the incidence of lymphatic vessel and venous invasion. Virchows Arch 2010; 456: 609-614
• 233 Buskens CJ et al. Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc 2004; 60: 703-710
• 234 Westerterp M et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch 2005; 446: 497-504
• 235 Ancona E et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol 2008; 15: 3278-3288
• 236 Liu L et al. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol 2005; 29: 1079-1085
• 237 Sepesi B et al. Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg 2010; 210: 418-427
• 238 Badreddine RJ et al. Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol 2010; 8: 248-253
• 239 Griffin SM, Burt AD, Jennings NA. Lymph node metastasis in early esophageal adenocarcinoma. Ann Surg 2011; 254: 731-736 ; discussion 736 – 737
• 240 Leers JM et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg 2011; 253: 271-278
• 241 Lorenz D et al. Prognostic risk factors of early esophageal adenocarcinomas. Ann Surg 2014; 259: 469-476
• 242 May A et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002; 14: 1085-1091
• 243 Gossner L et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998; 114: 448-455
• 244 Pech O et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 2005; 62: 24-30
• 245 Overholt BF et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007; 66: 460-468
• 246 Shaheen NJ et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009; 360: 2277-2288
• 247 Shaheen NJ et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011; 141: 460-468
• 248 Ganz RA et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc 2008; 68: 35-40
• 249 Phoa KN et al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013; 145: 96-104
• 250 Orman ES et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation. Am J Gastroenterol 2013; 108: 187-195 ; quiz 196
• 251 Van Laethem JL et al. Argon plasma coagulation in the treatment of Barrett's high-grade dysplasia and in situ adenocarcinoma. Endoscopy 2001; 33: 257-261
• 252 Ragunath K et al. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol 2005; 40: 750-758
• 253 Kelty CJ et al. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 2004; 20: 1289-1296
• 254 Dumot JA et al. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc 2009; 70: 635-644
• 255 Shaheen NJ et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2010; 71: 680-685
• 256 Ishihara R et al. Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan. Gastrointest Endosc 2008; 68: 1066-1072
• 257 Cao Y et al. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy 2009; 41: 751-757
• 258 Srivastava A et al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2007; 102: 483-493 ; quiz 694
• 259 Phoa KN et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. Jama 2014; 311: 1209-1217
• 260 McCann P et al. The safety and effectiveness of endoscopic and non-endoscopic approaches to the management of early esophageal cancer: a systematic review (Structured abstract). Cancer Treatment Reviews 2011; 1
• 261 Haidry RJ et al. Radiofrequency ablation for early oesophageal squamous neoplasia: outcomes form United Kingdom registry. World J Gastroenterol 2013; 19: 6011-6019
• 262 Min BH et al. Feasibility and efficacy of argon plasma coagulation for early esophageal squamous cell neoplasia. Endoscopy 2013; 45: 575-578
• 263 Tahara K et al. Argon plasma coagulation for superficial esophageal squamous-cell carcinoma in high-risk patients. World J Gastroenterol 2012; 18: 5412-5417
• 264 Peters FP et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus. Gastrointest Endosc 2005; 61: 506-514
• 265 Metzger R et al. High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality?. Dis Esophagus 2004; 17: 310-314
• 266 Holscher AH et al. High-volume centers--effect of case load on outcome in cancer surgery. Onkologie 2004; 27: 412-426
• 267 Coupland VH et al. Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004–2008. Gut 2013; 62: 961-966
• 268 Brusselaers N, Mattsson F, Lagergren J. Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. Gut 2014; 63: 1393-1400
• 269 Derogar M et al. Hospital and surgeon volume in relation to survival after esophageal cancer surgery in a population-based study. J Clin Oncol 2013; 31: 551-557
• 270 Reames BN, Shubeck SP, Birkmeyer JD. Strategies for reducing regional variation in the use of surgery: a systematic review. Ann Surg 2014; 259: 616-627
• 271 Schroder W et al. Preoperative risk analysis--a reliable predictor of postoperative outcome after transthoracic esophagectomy?. Langenbecks Arch Surg 2006; 391: 455-460
• 272 Bollschweiler E et al. Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus. Br J Surg 2000; 87: 1106-1110
• 273 Lagarde SM et al. Evaluation of O-POSSUM in predicting in-hospital mortality after resection for oesophageal cancer. Br J Surg 2007; 94: 1521-1526
• 274 Hodari A et al. Assessment of morbidity and mortality after esophagectomy using a modified frailty index. Ann Thorac Surg 2013; 96: 1240-1245
• 275 Pottgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer – a meta-analysis of the randomized trials. Cancer Treat Rev 2012; 38: 599-604
• 276 Markar SR et al. Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy: systematic review and pooled analysis. Ann Surg Oncol 2014; 21: 922-931
• 277 Hofstetter WL. Salvage esophagectomy. J Thorac Dis 2014; 6: S341-S349
• 278 Wu J et al. Prognostic significance of positive circumferential resection margin in esophageal cancer: a systematic review and meta-analysis. Ann Thorac Surg 2014; 97: 446-453
• 279 Holscher AH et al. How safe is high intrathoracic esophagogastrostomy?. Chirurg 2003; 74: 726-733
• 280 Holscher AH et al. Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann Surg 2007; 245: 241-246
• 281 Schroder W et al. The resection of the azygos vein--necessary or redundant extension of transthoracic esophagectomy?. J Gastrointest Surg 2008; 12: 1163-1167
• 282 Boone J et al. The effect of azygos vein preservation on mediastinal lymph node harvesting in thoracic esophagolymphadenectomy. Dis Esophagus 2008; 21: 226-229
• 283 Siewert JR et al. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg 1987; 58: 25-32
• 284 Kutup A et al. What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic versus transhiatal esophagectomy. Ann Surg 2014; 260: 1016-1022
• 285 Omloo JM et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007; 246: 992-1000 ; discussion 1000 – 1001
• 286 Sasako M et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006; 7: 644-651
• 287 Moehler M et al. German S3-guideline „Diagnosis and treatment of esophagogastric cancer“. Z Gastroenterol 49: 461-531
• 288 Peyre CG et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008; 248: 549-556
• 289 Peyre CG et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008; 248: 979-985
• 290 Lerut T et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004; 240: 962-972 ; discussion 972 – 974
• 291 Rizk NP et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg 2010; 251: 46-50
• 292 Fujita H et al. Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy. World J Surg 2003; 27: 571-579
• 293 Bollschweiler E et al. Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer. Ann Surg Oncol 2010; 17: 3187-3194
• 294 Bekkar S et al. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma. Ann Thorac Surg 2014; 97: 303-310
• 295 Wittekind CMeyer HJ. TNM: Klassifikation maligner Tumoren. 7. Auflage. Wiley; 2012: 315
• 296 Gutschow CA et al. Merendino procedure with preservation of the vagus for early carcinoma of the gastroesophageal junction. Zentralbl Chir 2004; 129: 276-281
• 297 Stein HJ et al. Limited resection for early adenocarcinoma in Barrett's esophagus. Ann Surg 2000; 232: 733-742
• 298 Zapletal C et al. Quality of life after surgical treatment of early Barrett's cancer: a prospective comparison of the Ivor-Lewis resection versus the modified Merendino resection. World J Surg 2014; 38: 1444-1452
• 299 Schroder W et al. Ivor-Lewis esophagectomy with and without laparoscopic conditioning of the gastric conduit. World J Surg 2010; 34: 738-743
• 300 Urschel JD et al. Pyloric drainage (pyloroplasty) or no drainage in gastric reconstruction after esophagectomy: a meta-analysis of randomized controlled trials. Dig Surg 2002; 19: 160-164
• 301 Gaur P, Swanson SJ. Should we continue to drain the pylorus in patients undergoing an esophagectomy?. Dis Esophagus 2014; 27: 568-573
• 302 Vallbohmer D et al. Diaphragmatic hernia after conventional or laparoscopic-assisted transthoracic esophagectomy. Ann Thorac Surg 2007; 84: 1847-1852
• 303 Price TN et al. A comprehensive review of anastomotic technique in 432 esophagectomies. Ann Thorac Surg 2013; 95: 1154-1160 ; discussion 1160 – 1161
• 304 Erkmen CP et al. Laparoscopic repair of hiatal hernia after esophagectomy. J Gastrointest Surg 2013; 17: 1370-1374
• 305 Avery KN et al. The feasibility of a randomized controlled trial of esophagectomy for esophageal cancer--the ROMIO (Randomized Oesophagectomy: Minimally Invasive or Open) study: protocol for a randomized controlled trial. Trials 2014; 15: 200
• 306 Biere SS et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012; 379: 1887-1892
• 307 Luketich JD et al. Outcomes after minimally invasive esophagectomy: review of over 1000 patients. Ann Surg 2012; 256: 95-103
• 308 Smithers BM et al. Comparison of the outcomes between open and minimally invasive esophagectomy. Ann Surg 2007; 245: 232-240
• 309 Briez N et al. Effects of hybrid minimally invasive oesophagectomy on major postoperative pulmonary complications. Br J Surg 2012; 99: 1547-1553
• 310 Briez N et al. Is minimally invasive oesophagectomy for cancer decreasing pulmonary complications-Results from a case-control study. J Clin Oncol 2010; 28: 15s
• 311 Bronson NW et al. The incidence of hiatal hernia after minimally invasive esophagectomy. J Gastrointest Surg 2014; 18: 889-893
• 312 Willer BL et al. Incidence of diaphragmatic hernias following minimally invasive versus open transthoracic Ivor Lewis McKeown esophagectomy. Hernia 2012; 16: 185-190
• 313 Erhunmwunsee L et al. Impact of pretreatment imaging on survival of esophagectomy after induction therapy for esophageal cancer: who should be given the benefit of the doubt?: esophagectomy outcomes of patients with suspicious metastatic lesions. Ann Surg Oncol 2015; 22: 1020-1025
• 314 Shimoji H et al. Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg 2013; 37: 2180-2188
• 315 Weimann A et al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. Clin Nutr 2006; 25: 224-244
• 316 Weimann A, Breitenstein S, Breuer JP et al. S3-Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin: Klinische Ernährung in der Chirurgie. Aktuell Ernährungsmedizin 2013; 38: e155-e197
• 317 Kondrup J et al. ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003; 22: 415-421
• 318 Schwegler I et al. Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer. Br J Surg 2010; 97: 92-97
• 319 Sorensen J et al. EuroOOPS: an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome. Clin Nutr 2008; 27: 340-349
• 320 Kuppinger D et al. Nutritional screening for risk prediction in patients scheduled for abdominal operations. Br J Surg 2012; 99: 728-737
• 321 Khuri SF et al. Risk adjustment of the postoperative mortality rate for the comparative assessment of the quality of surgical care: results of the National Veterans Affairs Surgical Risk Study. J Am Coll Surg 1997; 185: 315-327
• 322 Hennessey DB et al. Preoperative hypoalbuminemia is an independent risk factor for the development of surgical site infection following gastrointestinal surgery: a multi-institutional study. Ann Surg 2010; 252: 325-329
• 323 Ligthart-Melis GC et al. Dietician-delivered intensive nutritional support is associated with a decrease in severe postoperative complications after surgery in patients with esophageal cancer. Dis Esophagus 2013; 26: 587-593
• 324 Ellrichmann M et al. Prospective evaluation of malignant cell seeding after percutaneous endoscopic gastrostomy in patients with oropharyngeal/esophageal cancers. Endoscopy 2013; 45: 526-531
• 325 Mabvuure NT, Roman A, Khan OA. Enteral immunonutrition versus standard enteral nutrition for patients undergoing oesophagogastric resection for cancer. Int J Surg 2013; 11: 122-127
• 326 Osland E et al. Effect of timing of pharmaconutrition (immunonutrition) administration on outcomes of elective surgery for gastrointestinal malignancies: a systematic review and meta-analysis. JPEN J Parenter Enteral Nutr 2014; 38: 53-69
• 327 Jie B et al. Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk. Nutrition 2012; 28: 1022-1027
• 328 Hill GL. Impact of nutritional support on the clinical outcome of the surgical patient. Clin Nutr 1994; 13: 331-340
• 329 Burden S et al. Pre-operative nutrition support in patients undergoing gastrointestinal surgery. Cochrane Database Syst Rev 2012; 11: Cd008879
• 330 Bozzetti F et al. Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial. JPEN J Parenter Enteral Nutr 2000; 24: 7-14
• 331 Perioperative Total Parenteral Nutrition in Surgical Patients. New England Journal of Medicine 1991; 325: 525-532
• 332 Andersen HK, Lewis SJ, Thomas S. Early enteral nutrition within 24h of colorectal surgery versus later commencement of feeding for postoperative complications. Cochrane Database Syst Rev 2006; Cd004080
• 333 Lewis SJ, Andersen HK, Thomas S. Early enteral nutrition within 24h of intestinal surgery versus later commencement of feeding: a systematic review and meta-analysis. J Gastrointest Surg 2009; 13: 569-575
• 334 Osland E et al. Early versus traditional postoperative feeding in patients undergoing resectional gastrointestinal surgery: a meta-analysis. JPEN J Parenter Enteral Nutr 2011; 35: 473-487
• 335 Sica GS et al. Needle catheter jejunostomy at esophagectomy for cancer. J Surg Oncol 2005; 91: 276-279
• 336 Han-Geurts IJ et al. Randomized clinical trial comparing feeding jejunostomy with nasoduodenal tube placement in patients undergoing oesophagectomy. Br J Surg 2007; 94: 31-35
• 337 Gerritsen A et al. Efficacy and complications of nasojejunal, jejunostomy and parenteral feeding after pancreaticoduodenectomy. J Gastrointest Surg 2012; 16: 1144-1151
• 338 Markides GA, Alkhaffaf B, Vickers J. Nutritional access routes following oesophagectomy – a systematic review. Eur J Clin Nutr 2011; 65: 565-573
• 339 Theologou T et al. The impact of positive circumferential margin on survival following oesophagectomy using the new 7th TNM classification. Eur J Cardiothorac Surg 2013; 44: 855-859
• 340 O'Farrell NJ et al. Lack of independent significance of a close (<1 mm) circumferential resection margin involvement in esophageal and junctional cancer. Ann Surg Oncol 2013; 20: 2727-2733
• 341 Fok M et al. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993; 113: 138-147
• 342 Teniere P et al. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet 1991; 173: 123-130
• 343 Bao Y et al. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern. Radiat Oncol 2013; 8: 241
• 344 Jingu K et al. Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. BMC Cancer 2012; 12: 542
• 345 Ma DY et al. Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study. Radiat Oncol 2014; 9: 28
• 346 Fakhrian K et al. Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol 2012; 188: 136-142
• 347 Sudo K et al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol 2013; 31: 4306-4310
• 348 Oppedijk V et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol 2014; 32: 385-391
• 349 Malthaner RA et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004; 2: 35
• 350 Arnott SJ et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005; Cd001799
• 351 Schwer AL et al. Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. Int J Radiat Oncol Biol Phys 2009; 73: 449-455
• 352 Ychou M et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721
• 353 Cunningham D et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20
• 354 Kelsen DP et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984
• 355 Boonstra JJ et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer 2011; 11: 181
• 356 Allum WH et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-5067
• 357 Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727-1733
• 358 Law S et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997; 114: 210-217
• 359 Cunningham D, Allum W, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial of the UK NCRI Upper GI Clinical Studies Group (the MAGIC trial, ISRCTN 93793971) [abstract]. European journal of cancer 2003; 1: S18
• 360 Clark PI. Medical Research Council (MRC) randomised phase III trial of surgery with or without pre-operative chemotherapy in resectable cancer of the oesophagus. British journal of cancer 2000; 83: 1
• 361 Moehler M et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer 2014;
• 362 Sjoquist KM et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692
• 363 Fiorica F et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53: 925-930
• 364 Burmeister BH et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6: 659-668
• 365 Lee JL et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004; 15: 947-954
• 366 Bosset JF et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337: 161-167
• 367 Tepper J et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-1092
• 368 Stahl M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856
• 369 van Hagen P et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
• 370 Urba SG et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-313
• 371 Conroy T et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5 / ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014; 15: 305-314
• 372 van Hagen P et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
• 373 Herskovic A et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-1598
• 374 Cao XF et al. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus 2009; 22: 477-481
• 375 Walsh TN et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467
• 376 Walsh TN, Grannell M, Mansoor S. Predictive factors for success of neo-adjuvant therapy in upper gastrointestinal cancer. J Gastroenterol Hepatol 2002; 17: S172-S175
• 377 Walsh TN et al. Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Dis Esophagus 2002; 15: 121-124
• 378 Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994; 41: 391-393
• 379 Le Prise E et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994; 73: 1779-1784
• 380 Kumagai K et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br J Surg 2014; 101: 321-338
• 381 Ronellenfitsch U et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database of Systematic Reviews 2013;
• 382 Lone GN et al. Role of preoperative chemotherapy in squamous cell carcinoma of esophagus in kashmir, a cancer belt – a pilot study. Asian Pac J Cancer Prev 2011; 12: 465-470
• 383 Sjoquist KM et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12: 681-692
• 384 Kranzfelder M et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 2011; 98: 768-783
• 385 Ando N et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 2012; 19: 68-74
• 386 Lordick F. Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography. Recent Results Cancer Res 2012; 196: 201-211
• 387 Weber WA et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3065
• 388 Ott K et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24: 4692-4698
• 389 Ilson DH. Cancer of the gastroesophageal junction: combined modality therapy. Surg Oncol Clin N Am 2006; 15: 803-824
• 390 Wieder HA et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 2005; 46: 2029-2034
• 391 Lordick F et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8: 797-805
• 392 zum Buschenfelde CM et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 2011; 52: 1189-1196
• 393 Gillham CM et al. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006; 95: 1174-1179
• 394 Klaeser B et al. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie 2009; 32: 724-730
• 395 Malik V et al. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med 2010; 51: 1863-1869
• 396 van Heijl M et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 2011; 253: 56-63
• 397 Chang DT et al. Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis. Am J Clin Oncol 2009; 32: 405-410
• 398 Karran A et al. Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy. Br J Surg 2014; 101: 502-510
• 399 al-Sarraf M et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997; 15: 277-284
• 400 Crehange G et al. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102. J Clin Oncol 2007; 25: 4895-4901
• 401 Kawaguchi Y et al. Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer. Jpn J Clin Oncol 2011; 41: 1007-1012
• 402 Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006; Cd002092
• 403 Yamada K et al. Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma. Int J Radiat Oncol Biol Phys 2006; 64: 1106-1111
• 404 Kato H et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol 2009; 39: 638-643
• 405 Kuwano H et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus. Esophagus 2008; 5: 117-132
• 406 Gkika E et al. Long-term results of definitive radiochemotherapy in locally advanced cancers of the cervical esophagus. Dis Esophagus 2014; 27: 678-684
• 407 Grass GD et al. Cervical esophageal cancer: A population-based study. Head Neck 2014;
• 408 Burmeister BH et al. Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy. Arch Otolaryngol Head Neck Surg 2000; 126: 205-208
• 409 Ajani JA et al. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw 9: 830-887
• 410 Gao X. Treatment guideline of radiotherapy for Chinese esophageal carcinoma (draft). Chin J Cancer 2010; 29: 855-859
• 411 Fenkell L et al. Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. Radiother Oncol 2008; 89: 287-291
• 412 Ma JB et al. Feasibility of involved-field conformal radiotherapy for cervical and upper-thoracic esophageal cancer. Onkologie 2011; 34: 599-604
• 413 Ma JB et al. Feasibility of Involved-Field Conformal Radiotherapy for Cervical and Upper-Thoracic Esophageal Cancer. Oncology Research and Treatment 2011; 34: 599-604
• 414 Tai P et al. Improving the consistency in cervical esophageal target volume definition by special training. Int J Radiat Oncol Biol Phys 2002; 53: 766-774
• 415 Ott K et al. Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. Br J Surg 2009; 96: 258-266
• 416 Panhofer P et al. Influence of resection extent on morbidity in surgery for squamous cell cancer at the pharyngoesophageal junction. Langenbecks Arch Surg 2013; 398: 221-230
• 417 Kranzfelder M et al. Littoral cell angioma and angiosarcoma of the spleen: report of two cases in siblings and review of the literature. J Gastrointest Surg 2012; 16: 863-867
• 418 Bedenne L et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-1168
• 419 Minsky BD et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174
• 420 Ajani JA et al. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw 2011; 9: 830-887
• 421 Crosby T et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 2013; 14: 627-637
• 422 Meerten E et al. Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: A phase II study. ASCO Annual Meeting Proceedings 2010;
• 423 Suntharalingam M et al. The Initial Report of Local Control on RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Treated Without Surgery. International Journal of Radiation Oncology • Biology • Physics 90: S3
• 424 Stahl M et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317
• 425 Kole TP et al. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 2012; 83: 1580-1586
• 426 Lee HK et al. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys 2003; 57: 1317-1322
• 427 Ruol A et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?. Ann Surg 2010; 252: 788-796
• 428 Kim JY et al. Does the timing of esophagectomy after chemoradiation affect outcome?. Ann Thorac Surg 2012; 93: 207-212 ; discussion 212 – 213
• 429 Tachimori Y. Role of salvage esophagectomy after definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg 2009; 57: 71-78
• 430 Tomimaru Y et al. Factors affecting the prognosis of patients with esophageal cancer undergoing salvage surgery after definitive chemoradiotherapy. J Surg Oncol 2006; 93: 422-428
• 431 Marks JL et al. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. Ann Thorac Surg 2012; 94: 1126-1132 ; discussion 1132 – 1133
• 432 Taketa T et al. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology 2013; 85: 95-99
• 433 Ariga H et al. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2009; 75: 348-356
• 434 Zheng B et al. Role of adjuvant chemoradiotherapy in treatment of resectable esophageal carcinoma: a meta-analysis. Chin Med J (Engl.) 2013; 126: 1178-1182
• 435 Thallinger CM et al. Pre- and postoperative treatment modalities for esophageal squamous cell carcinoma. Anticancer Res 2012; 32: 4609-4627
• 436 Xu Y et al. Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?. World J Surg Oncol 2012; 10: 173
• 437 Lv J et al. Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol 2010; 16: 1649-1654
• 438 Cao XF et al. A prospective comparison between surgery alone and postoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi 2010; 32: 452-455
• 439 Ohri N et al. Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 2013; 86: 330-335
• 440 Bamias A et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol 2010; 65: 1009-1021
• 441 Lee J et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012; 30: 268-273
• 442 Macdonald JS et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730
• 443 Kwon HC et al. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol 2010; 6: 278-285
• 444 Paoletti X et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. Jama 2010; 303: 1729-1737
• 445 Abate E et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg 2010; 210: 428-435
• 446 Mantziari S et al. Gastroesophageal cancer: an update on diagnosis and treatment. Rev Med Suisse 2014; 10: 1331-1336
• 447 Ouattara M et al. Body mass index kinetics and risk factors of malnutrition one year after radical oesophagectomy for cancer. Eur J Cardiothorac Surg 2012; 41: 1088-1093
• 448 Haverkort EB et al. Suboptimal intake of nutrients after esophagectomy with gastric tube reconstruction. J Acad Nutr Diet 2012; 112: 1080-1087
• 449 Ryan AM et al. Post-oesophagectomy early enteral nutrition via a needle catheter jejunostomy: 8-year experience at a specialist unit. Clin Nutr 2006; 25: 386-393
• 450 Mishra SI et al. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev 2012; 8: Cd008465
• 451 Bourke L et al. Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review. Br J Cancer 2014; 110: 831-841
• 452 Rock CL et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62: 243-274
• 453 Mishra SI et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev 2012; 8: Cd007566
• 454 Cunningham D et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46
• 455 Webb A et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267
• 456 Ross P et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996-2004
• 457 Van Cutsem E et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997
• 458 Ajani JA et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28: 1547-1553
• 459 Al-Batran SE et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442
• 460 Kang YK et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20: 666-673
• 461 Okines AF et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20: 1529-1534
• 462 Lutz MP et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2007; 25: 2580-2585
• 463 Al-Batran SE et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008; 19: 1882-1887
• 464 NCCN Clinical Practice Guidelines in Oncology. Esophageal and Esophagastric Junction Cancers. National Comprehensive Cancer Network; 2011
• 465 Grunberger B et al. Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res 2007; 27: 2705-2714
• 466 NCCN practice guidelines for the management of psychosocial distress. National Comprehensive Cancer Network; 1999
• 467 Adam R et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1452 patients and development of a prognostic model. Ann Surg 2006; 244: 524-535
• 468 Shiono S et al. Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases. J Thorac Oncol 2008; 3: 1046-1049
• 469 Ichikawa H et al. Operative treatment for metachronous pulmonary metastasis from esophageal carcinoma. Surgery 2011; 149: 164-170
• 470 Ichida H et al. Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma. World J Surg 2013; 37: 398-407
• 471 Miyata H et al. Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol 2009; 100: 442-446
• 472 Morita M et al. Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy. J Gastroenterol 2011; 46: 1284-1291
• 473 Schieman C et al. Salvage resections for recurrent or persistent cancer of the proximal esophagus after chemoradiotherapy. Ann Thorac Surg 2013; 95: 459-463
• 474 Thuss-Patience PC et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306-2314
• 475 Hironaka S et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013; 31: 4438-4444
• 476 Ford HE et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 2014; 15: 78-86
• 477 Fuchs CS et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39
• 478 Wilke H et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235
• 479 Thallinger CM, Raderer M, Hejna M. Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol 2011; 29: 4709-4714
• 480 Amdal CD et al. Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review. Acta Oncol 2013; 52: 679-690
• 481 Sgourakis G et al. Survival after chemotherapy and/or radiotherapy versus self-expanding metal stent insertion in the setting of inoperable esophageal cancer: a case-control study. BMC Cancer 2012; 12: 70
• 482 Javed A et al. Palliative stenting with or without radiotherapy for inoperable esophageal carcinoma: a randomized trial. J Gastrointest Cancer 2012; 43: 63-69
• 483 Amdal CD et al. Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial. Radiother Oncol 2013; 107: 428-433
• 484 Homs MY et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004; 364: 1497-1504
• 485 Rosenblatt E et al. Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: a prospective multi-centre randomized trial of the International Atomic Energy Agency. Radiother Oncol 2010; 97: 488-494
• 486 Sgourakis G et al. The use of self-expanding stents in esophageal and gastroesophageal junction cancer palliation: a meta-analysis and meta-regression analysis of outcomes. Dig Dis Sci 2010; 55: 3018-3030
• 487 Sabharwal T et al. A randomised prospective comparison of the Flamingo Wallstent and Ultraflex stent for palliation of dysphagia associated with lower third oesophageal carcinoma. Gut 2003; 52: 922-926
• 488 Shenfine J et al. A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technol Assess 2005; 9: iii, 1-121
• 489 Vakil N et al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol 2001; 96: 1791-1796
• 490 Miyayama S et al. Malignant esophageal stricture and fistula: palliative treatment with polyurethane-covered Gianturco stent. J Vasc Interv Radiol 1995; 6: 243-248
• 491 Alexander EP et al. Evolving management and outcome of esophageal cancer with airway involvement. Ann Thorac Surg 2001; 71: 1640-1644
• 492 Conio M et al. A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia. Am J Gastroenterol 2007; 102: 2667-2677
• 493 Homs MY et al. Esophageal stents with antireflux valve for tumors of the distal esophagus and gastric cardia: a randomized trial. Gastrointest Endosc 2004; 60: 695-702
• 494 Shim CS et al. Management of malignant stricture of the esophagogastric junction with a newly designed self-expanding metal stent with an antireflux mechanism. Endoscopy 2005; 37: 335-339
• 495 Wenger U et al. An antireflux stent versus conventional stents for palliation of distal esophageal or cardia cancer: a randomized clinical study. Surg Endosc 2006; 20: 1675-1680
• 496 Bergquist H et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis.Esophagus 2005; 18: 131-139
• 497 Wenger U et al. Health economic evaluation of stent or endoluminal brachytherapy as a palliative strategy in patients with incurable cancer of the oesophagus or gastro-oesophageal junction: results of a randomized clinical trial. Eur J Gastroenterol Hepatol 2005; 17: 1369-1377
• 498 Bergquist H et al. Combined stent insertion and single high-dose brachytherapy in patients with advanced esophageal cancer--results of a prospective safety study. Dis Esophagus 2012; 25: 410-415
• 499 Carazzone A et al. Endoscopic palliation of oesophageal cancer: results of a prospective comparison of Nd:YAG laser and ethanol injection. Eur J Surg 1999; 165: 351-356
• 500 Spencer GM et al. Laser augmented by brachytherapy versus laser alone in the palliation of adenocarcinoma of the oesophagus and cardia: a randomised study. Gut 2002; 50: 224-227
• 501 Norberto L et al. Endoscopic palliation of esophageal and cardial cancer: neodymium-yttrium aluminum garnet laser therapy. Dis Esophagus 1999; 12: 294-296
• 502 Loizou LA et al. A prospective comparison of laser therapy and intubation in endoscopic palliation for malignant dysphagia. Gastroenterology 1991; 100: 1303-1310
• 503 Carter R, Smith JS, Anderson JR. Laser recanalization versus endoscopic intubation in the palliation of malignant dysphagia: a randomized prospective study. Br J Surg 1992; 79: 1167-1170
• 504 Barr H et al. Prospective randomised trial of laser therapy only and laser therapy followed by endoscopic intubation for the palliation of malignant dysphagia. Gut 1990; 31: 252-258
• 505 Manner H et al. The tissue effect of second generation argon plasma coagulation (VIO APC) in comparison to standard APC and Nd:YAG laser in vitro. Acta Gastroenterol Belg 2007; 70: 352-356
• 506 Eickhoff A et al. Prospective nonrandomized comparison of two modes of argon beamer (APC) tumor desobstruction: effectiveness of the new pulsed APC versus forced APC. Endoscopy 2007; 39: 637-642
• 507 Manner H et al. Prospective evaluation of a new high-power argon plasma coagulation system (hp-APC) in therapeutic gastrointestinal endoscopy. Scand J Gastroenterol 2007; 42: 397-405
• 508 Rupinski M et al. Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (Revised II). The American journal of gastroenterology 2011; 9
• 509 Dempster M et al. Psychological distress among survivors of esophageal cancer: the role of illness cognitions and coping. Dis Esophagus 2012; 25: 222-227
• 510 Djärv T, Lagergren P. Six-month postoperative quality of life predicts long-term survival after oesophageal cancer surgery. European journal of cancer 2011; 47: 530-535
• 511 Heijl M et al. Preoperative and Early Postoperative Quality of Life Predict Survival in Potentially Curable Patients with Esophageal Cancer. Annals of Surgical Oncology 2010; 17: 23-30
• 512 Gockel I et al. Long-term survivors of esophageal cancer: Disease-specific quality of life, general health and complications. Journal of Surgical Oncology 2010; 102: 516-522
• 513 National Comprehensive Cancer Network. Distress Management. NCCN Clinical Practice Guidelines in Oncology; 2011
• 514 Herschbach P, Weis J. Screeningverfahren in der Psychoonkologie.Testinstrumente zur Identifikation betreuungsbedürftiger Krebspatienten. Dt. Krebsgesellschaft; 2010 http://www.krebsgesellschaft.de/download/pso_broschuere.pdf
• 515 Mehnert A et al. Assessment of psychosocial distress and resources in oncology – a literature review about screening measures and current developments. Psychother Psychosom Med Psychol 2006; 56: 462-479
• 516 Mitchell AJ. Short screening tools for cancer-related distress: a review and diagnostic validity meta-analysis. J Natl Compr Canc Netw 2010; 8: 487-494
• 517 Vodermaier A, Linden W, Siu C. Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J Natl Cancer Inst 2009; 101: 1464-1488
• 518 Vodermaier A, Millman RD. Accuracy of the Hospital Anxiety and Depression Scale as a screening tool in cancer patients: a systematic review and meta-analysis. Support Care Cancer 2011; 19: 1899-1908
• 519 Weis J, Schumacher A, Blettner G. Psychoonkologie: Konzepte und Aufgaben einer jungen Fachdisziplin. Der Onkologe 2007; 13: 185-194
• 520 Faller H et al. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol 2013; 31: 782-793
• 521 Ä.Z.f.Q.i.d.M (Hrsg) Kompendium Q-M-A. Deutscher Ärzteverlag; 2008
• 522 Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q 1966; 44: 166-206
• 523 Ärztliches Zentrum für Qualität in der Medizin (ÄZQ). Manual Qualitätsindikatoren. Berlin: äzq Schriftenreihe; 2009
• 524 Low DE et al. International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy: Esophagectomy Complications Consensus Group (ECCG). Ann Surg 2015;
• 525 Vlayen J et al. Quality indicators for the management of upper gastrointestinal cancer. KCE, Editor; 2013
• 526 Walters DM et al. Understanding mortality as a quality indicator after esophagectomy. Ann Thorac Surg 2014; 98: 506-511 ; discussion 511–512
• 527 Talsma AK et al. The 30-day versus in-hospital and 90-day mortality after esophagectomy as indicators for quality of care. Ann Surg 2014; 260: 267-273